GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transcenta Holding Ltd (HKSE:06628) » Definitions » Gross-Profit-to-Asset %

Transcenta Holding (HKSE:06628) Gross-Profit-to-Asset % : 0.19% (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Transcenta Holding Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Transcenta Holding's annualized Gross Profit for the quarter that ended in Jun. 2024 was HK$3.28 Mil. Transcenta Holding's average Total Assets over the quarter that ended in Jun. 2024 was HK$1,719.06 Mil. Therefore, Transcenta Holding's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2024 was 0.19%.


Transcenta Holding Gross-Profit-to-Asset % Historical Data

The historical data trend for Transcenta Holding's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transcenta Holding Gross-Profit-to-Asset % Chart

Transcenta Holding Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
0.44 1.02 0.41 0.81 0.74

Transcenta Holding Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.24 1.44 0.98 0.47 0.19

Competitive Comparison of Transcenta Holding's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Transcenta Holding's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Transcenta Holding's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Transcenta Holding's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Transcenta Holding's Gross-Profit-to-Asset % falls into.



Transcenta Holding Gross-Profit-to-Asset % Calculation

Transcenta Holding's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=15.748/( (2383.678+1852.095)/ 2 )
=15.748/2117.8865
=0.74 %

Transcenta Holding's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Jun. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Jun. 2024 ))/ count )
=3.282/( (1852.095+1586.018)/ 2 )
=3.282/1719.0565
=0.19 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Jun. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Transcenta Holding Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Transcenta Holding's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Transcenta Holding Business Description

Traded in Other Exchanges
N/A
Address
B6-501, 218 Xinghu Street, Biobay, Suzhou, CHN, 215123
Transcenta Holding Ltd is a clinical-stage biopharmaceutical company with fully integrated capacities in discovery, research, development, and manufacturing. It is developing nine therapeutic antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders. Geographically the company operates in China (the PRC) and the USA.
Executives
Qian Xueming 2101 Beneficial owner
Shi Xiaohong 2501 Other
Lav Corporate Gp, Ltd. 2201 Interest of corporation controlled by you
Lav Gp Iii, L.p. 2201 Interest of corporation controlled by you
Lav Biosciences Fund Iii, L.p. 2101 Beneficial owner
Shi Yi 2201 Interest of corporation controlled by you
Lav Asset Management (hong Kong) Limited 2102 Investment manager
Fullerton Management Pte Ltd
Temasek Life Sciences Private Limited
Tls Beta Pte. Ltd.
Hsbc Trust Company (delaware), N.a. 2301 Trustee
Success Link International L.p. 2101 Beneficial owner
Temasek Holdings (private) Limited
Lav Vitality Limited 2101 Beneficial owner
Zhong Guo Guo You Qi Ye Jie Gou Tiao Zheng Ji Jin Gu Fen You Xian Gong Si 2501 Other

Transcenta Holding Headlines

No Headlines